Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132808 · ClinicalTrials.gov registry record · Phase 3
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 581
- Enrollment target
NCT00132808 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 581 participants.
The verdict
NCT00132808, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 581 participants
- Enrollment target
Study Summary
Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.
Interventions
- DRUG Placebo
- DRUG Zoledronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00132808
The ClinicalTrials.gov registry entry for NCT00132808 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 581 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00132808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00132808 about?
NCT00132808 is a clinical study titled "Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older". Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.
What is the current status of trial NCT00132808?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 581 participants. The study started on 2004-07. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00132808?
The interventions under investigation include: Placebo (DRUG), Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT00132808?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.